ATE367163T1 - 4-(sulfanylpyrimidin-4-ylmethyl)morpholin- derivate und verwandte verbindungen als gaba- rezeptorliganden zur behandlung von angst, depression und epilepsie - Google Patents
4-(sulfanylpyrimidin-4-ylmethyl)morpholin- derivate und verwandte verbindungen als gaba- rezeptorliganden zur behandlung von angst, depression und epilepsieInfo
- Publication number
- ATE367163T1 ATE367163T1 AT05707562T AT05707562T ATE367163T1 AT E367163 T1 ATE367163 T1 AT E367163T1 AT 05707562 T AT05707562 T AT 05707562T AT 05707562 T AT05707562 T AT 05707562T AT E367163 T1 ATE367163 T1 AT E367163T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- sub
- atom
- epilepsy
- anxiety
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 206010015037 epilepsy Diseases 0.000 title abstract 2
- 102000005915 GABA Receptors Human genes 0.000 title 1
- 108010005551 GABA Receptors Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- DKBOWAZIJFEFCD-UHFFFAOYSA-N morpholin-4-yl(pyrimidin-4-yl)methanethiol Chemical class C=1C=NC=NC=1C(S)N1CCOCC1 DKBOWAZIJFEFCD-UHFFFAOYSA-N 0.000 title 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000002740 Muscle Rigidity Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 206010008129 cerebral palsy Diseases 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 235000019788 craving Nutrition 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04100830 | 2004-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE367163T1 true ATE367163T1 (de) | 2007-08-15 |
Family
ID=34896109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05707562T ATE367163T1 (de) | 2004-03-02 | 2005-02-22 | 4-(sulfanylpyrimidin-4-ylmethyl)morpholin- derivate und verwandte verbindungen als gaba- rezeptorliganden zur behandlung von angst, depression und epilepsie |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7351700B2 (de) |
| EP (1) | EP1725239B1 (de) |
| JP (1) | JP4563447B2 (de) |
| KR (1) | KR100802863B1 (de) |
| CN (1) | CN1925859B (de) |
| AT (1) | ATE367163T1 (de) |
| AU (1) | AU2005229505B2 (de) |
| BR (1) | BRPI0508310A (de) |
| CA (1) | CA2557719A1 (de) |
| DE (1) | DE602005001696T2 (de) |
| ES (1) | ES2290885T3 (de) |
| PL (1) | PL1725239T3 (de) |
| RU (1) | RU2382033C2 (de) |
| WO (1) | WO2005094828A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2353619C2 (ru) * | 2007-06-28 | 2009-04-27 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции |
| RU2354647C2 (ru) * | 2007-06-28 | 2009-05-10 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе |
| AU2008273889B2 (en) * | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| TW201623257A (zh) | 2014-05-09 | 2016-07-01 | 奧利安公司 | 藥理活性之喹唑啉二酮衍生物 |
| KR102269132B1 (ko) | 2014-06-10 | 2021-06-25 | 삼성디스플레이 주식회사 | 반방향족성 화합물 및 이를 포함하는 유기 발광 소자 |
| US10084141B2 (en) | 2014-06-13 | 2018-09-25 | Samsung Display Co., Ltd. | Antiaromatic compound and organic light-emitting device including the same |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| WO2022029666A1 (en) | 2020-08-05 | 2022-02-10 | Richter Gedeon Nyrt. | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| JP3398152B2 (ja) * | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| WO2001056990A2 (en) | 2000-02-03 | 2001-08-09 | Eli Lilly And Company | Pyridine derivates as potentiators of glutamate receptors |
| EP1385831A2 (de) * | 2001-04-11 | 2004-02-04 | Queen's University At Kingston | Pyrimidderivate zur behandlung von epilepsie |
| GB0209481D0 (en) | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
-
2005
- 2005-02-22 ES ES05707562T patent/ES2290885T3/es not_active Expired - Lifetime
- 2005-02-22 JP JP2007501167A patent/JP4563447B2/ja not_active Expired - Fee Related
- 2005-02-22 CA CA002557719A patent/CA2557719A1/en not_active Abandoned
- 2005-02-22 RU RU2006134632/04A patent/RU2382033C2/ru not_active IP Right Cessation
- 2005-02-22 AU AU2005229505A patent/AU2005229505B2/en not_active Ceased
- 2005-02-22 BR BRPI0508310-9A patent/BRPI0508310A/pt not_active IP Right Cessation
- 2005-02-22 DE DE602005001696T patent/DE602005001696T2/de not_active Expired - Lifetime
- 2005-02-22 KR KR1020067017683A patent/KR100802863B1/ko not_active Expired - Fee Related
- 2005-02-22 PL PL05707562T patent/PL1725239T3/pl unknown
- 2005-02-22 AT AT05707562T patent/ATE367163T1/de active
- 2005-02-22 WO PCT/EP2005/001814 patent/WO2005094828A1/en not_active Ceased
- 2005-02-22 CN CN2005800066192A patent/CN1925859B/zh not_active Expired - Fee Related
- 2005-02-22 EP EP05707562A patent/EP1725239B1/de not_active Expired - Lifetime
- 2005-02-23 US US11/064,046 patent/US7351700B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL1725239T3 (pl) | 2007-12-31 |
| RU2382033C2 (ru) | 2010-02-20 |
| CN1925859A (zh) | 2007-03-07 |
| KR20060116240A (ko) | 2006-11-14 |
| DE602005001696T2 (de) | 2008-04-10 |
| EP1725239B1 (de) | 2007-07-18 |
| CN1925859B (zh) | 2010-11-24 |
| AU2005229505A1 (en) | 2005-10-13 |
| CA2557719A1 (en) | 2005-10-13 |
| EP1725239A1 (de) | 2006-11-29 |
| JP2007526266A (ja) | 2007-09-13 |
| BRPI0508310A (pt) | 2007-07-24 |
| US7351700B2 (en) | 2008-04-01 |
| DE602005001696D1 (de) | 2007-08-30 |
| JP4563447B2 (ja) | 2010-10-13 |
| WO2005094828A1 (en) | 2005-10-13 |
| AU2005229505B2 (en) | 2010-07-15 |
| KR100802863B1 (ko) | 2008-02-12 |
| US20050197337A1 (en) | 2005-09-08 |
| ES2290885T3 (es) | 2008-02-16 |
| RU2006134632A (ru) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011313A (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
| NZ590951A (en) | Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders | |
| HUP0301866A2 (hu) | Azabiciklusos karbamátok mint alfa-7 nikotin/acetilkolin receptor agonisták, eljárás elżállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| ATE451373T1 (de) | N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| MXPA06011194A (es) | Tiadiazolidinonas como inhibidores de gsk-3. | |
| PH12015502001A1 (en) | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| EA201000332A1 (ru) | 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны | |
| WO2012042539A3 (en) | 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders | |
| EP2187888A2 (de) | Bicyclische amide zur verbesserung der glutaminergen synaptischen antworten | |
| HK62692A (en) | (r)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide | |
| NO20092198L (no) | Nye Triazindionderivater som GABA-B-reseptormodulatorer | |
| JP2007500168A5 (de) | ||
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| ATE367163T1 (de) | 4-(sulfanylpyrimidin-4-ylmethyl)morpholin- derivate und verwandte verbindungen als gaba- rezeptorliganden zur behandlung von angst, depression und epilepsie | |
| WO2007054444A3 (en) | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | |
| DE602005008633D1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin-derivative zur behandlung kognitiver störungen | |
| CH634576A5 (de) | Verfahren zur herstellung von aminoalkylpyrrolbenzoxaazaalkanen. | |
| EP0473550A1 (de) | Indolonaphthyridine | |
| EA200870492A1 (ru) | N-оксиды производных пиридилметилпиперазина и - пиперидина | |
| Choi et al. | Facile synthesis and biological evaluation of 3, 3-diphenylpropanoyl piperazines as T-type calcium channel blockers | |
| Linzaga et al. | NMR and X-ray crystallographic studies of axial and equatorial 2-ethoxy-2-oxo-1, 4, 2-oxazaphosphinane | |
| NL8204462A (nl) | Benzylideenderivaten, de bereiding hiervan en de therapeutische toepassing. | |
| DE602007012683D1 (de) | Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente | |
| JP2008509925A (ja) | 新規のセロトニンレセプターリガンドおよびそれらの使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1725239 Country of ref document: EP |